NCT07227597 2026-02-20
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT06610734 2026-02-09
SKY
Sichuan University
Phase 2 Recruiting
NCT05703971 2025-10-16
Acclaim-3
Genprex, Inc.
Phase 1/2 Recruiting
NCT06429696 2025-05-28
PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT05680922 2025-05-22
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Legend Biotech USA Inc
Phase 1 Recruiting
NCT06348797 2025-05-16
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
Sichuan University
Phase 1 Recruiting
NCT06030258 2025-04-30
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting